Aug 12, 2020
Potential Enhancement of Prostate Cancer Treatment Options: First Patient Randomized in Phase III Trial
Jun 22, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
Jun 17, 2020
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting
Jun 15, 2020
Global Prostate Cancer Market Analysis to 2028 - Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
May 29, 2020
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
May 29, 2020
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
May 27, 2020
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
May 15, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
May 07, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
Mar 31, 2020
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
Mar 09, 2020
The global prostate cancer treatment market was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026
Feb 27, 2020
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 13, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
Feb 13, 2020
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Feb 11, 2020
XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC
Feb 10, 2020
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
Dec 19, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
Dec 16, 2019
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer
Nov 25, 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Nov 25, 2019
Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)